Keytruda is an immunotherapy medication developed by Merck & Co., approved for the treatment of multiple cancers including melanoma, lung cancer, and head and neck cancers. It works by blocking the PD-1 receptor, enabling the immune system to better recognize and attack cancer cells. Since its FDA approval in 2014, Keytruda has become a leading checkpoint inhibitor in oncology, with ongoing research expanding its potential uses.